Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Affiliation auteurs!!!! Error affiliation !!!!
TitreYttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study
Type de publicationJournal Article
Year of Publication2015
Auteurs, Abraham J, Amorim S, Herbaux C, Philippe L, Andre M, Parcelier A, Fruchart C, Bouabdallah K, Cornillon J, Cherrier S, Salvado C, Drenou B, Oberic L, Quittet P, Venton G, Calmettes C, Chebrek S, Rossi C, Campidelli A, Lioure B, Auger S, Altounian L, Mineur P, Woff E, Peyrade F
JournalBLOOD
Volume126
Date PublishedDEC 3
Type of ArticleMeeting Abstract
ISSN0006-4971